Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
about
Ceramide Synthase 6 Is a Novel Target of Methotrexate Mediating Its Antiproliferative Effect in a p53-Dependent MannerAutophagy and cancer therapy.Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effectsDifferential regulation of autophagy and cell viability by ceramide species.The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.Phase I study of pemetrexed with sorafenib in advanced solid tumors.HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cellsSrc mediates extracellular signal-regulated kinase 1/2 activation and autophagic cell death induced by cardiac glycosides in human non-small cell lung cancer cell lines.[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.In vitro genotoxicity and cytotoxicity of a particular combination of pemetrexed and cefixime in human peripheral blood lymphocytes.ERK plays the baddie (again).Ceramide in the prostate.PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.
P2860
Q28552611-BB3AF305-7155-4910-9FEB-36B70FD52D9BQ33584607-1D528030-7471-4B39-8E4F-9EA40C338F6CQ34276149-3A079301-B00A-48C4-8A46-2F2B75F9F5A4Q35552005-36E96D8C-7EB2-4DE8-B600-7C3C2BEF03F9Q36214943-A3A00250-CFDC-493B-A9FE-B5554DD99D79Q37190128-E2FA66A9-A15F-4230-A846-19AF75E9280BQ37520649-3812F899-E1BC-4F16-B44F-45D60218B4B5Q37683049-7B3BF43D-569E-4237-8B20-091FA3E478FDQ39017201-34A60656-58EF-4EAD-8AED-1E55A6E793F5Q39888747-4BD9C29B-EE46-4D0E-8941-5508993DE130Q41929082-ACF316B8-87CE-46DB-AA86-DB9E3854A0FCQ41958095-A50FD5EF-6B5E-4884-B6F4-0EE318CA7663Q41960726-86CF0FC8-1631-42BD-820D-CEA3DCDD84F9Q47271622-E32FCB8E-D4EA-4BE1-8323-123996F270BD
P2860
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
@en
type
label
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
@en
prefLabel
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
@en
P2093
P2860
P356
P1476
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
@en
P2093
Andrew Poklepovic
Besim Ogretmen
Hossein A Hamed
Jeremy Allegood
M Danielle Bareford
Margaret A Park
Nichola Cruickshanks
Steven Grant
P2860
P304
P356
10.4161/CBT.20562
P577
2012-06-07T00:00:00Z